Seqens Seqens

X
[{"orgOrder":0,"company":"Rhoshan Pharmaceuticals","sponsor":"Hyloris Pharmaceuticals","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"$0.7 million","newsHeadline":"Hyloris Acquires Breakthrough, Patented Technology to Develop and Market Aspirin IV in the U.S. in Acute Coronary Syndrome","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Rhoshan Pharmaceuticals

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Under the terms of the agreement, Hyloris acquires the worldwide license to all intellectual property rights, and technical proprietary information in relation to the IV formulation technology to develop intravenous acetylsalicylic acid (HY-073) in multiple indications.

            Lead Product(s): Aspirin

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: HY-073

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Hyloris Pharmaceuticals

            Deal Size: $7.5 million Upfront Cash: $0.7 million

            Deal Type: Licensing Agreement October 13, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY